Literature DB >> 7533783

Molecular basis of CD36 deficiency. Evidence that a 478C-->T substitution (proline90-->serine) in CD36 cDNA accounts for CD36 deficiency.

H Kashiwagi1, Y Tomiyama, S Honda, S Kosugi, M Shiraga, N Nagao, S Sekiguchi, Y Kanayama, Y Kurata, Y Matsuzawa.   

Abstract

CD36 deficiency is divided into two subgroups: neither platelets nor monocytes express CD36 (type I deficiency), and monocytes express CD36 in spite of the lack of platelet CD36 (type II deficiency). We have already demonstrated that a 478C-->T substitution (proline90-->serine) in platelet CD36 cDNA predominates in type II deficiency (Kashiwagi, H., S. Honda, Y. Tomiyama, H. Mizutani, H. Take, Y. Honda, S. Kosugi, Y. Kanayama, Y. Kurata, and Y. Matsuzawa. 1993. Thromb. Haemostasis. 69:481-484). In this study, we revealed that monocyte CD36 cDNA from two type II deficient subjects was heterozygous for C478 and T478 form, while platelet CD36 cDNA of these subjects consisted of only T478 form. In a type I deficient subject, both platelet and monocyte CD36 cDNA showed only T478 form. Expression assay using C478 or T478 form of CD36 cDNA transfected cells revealed that there was an 81-kD precursor form of CD36, and that the maturation of the 81-kD precursor form to the 88-kD mature form of CD36 was markedly impaired by the substitution. The mutated precursor form of CD36 was subsequently degraded in the cytoplasm. These results indicate that the 478C-->T substitution directly leads to CD36 deficiency via defects in posttranslational modification, and that this substitution is the major defects underlying CD36 deficiency.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7533783      PMCID: PMC441438          DOI: 10.1172/JCI117749

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

Review 1.  Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine.

Authors:  D E Greenwalt; R H Lipsky; C F Ockenhouse; H Ikeda; N N Tandon; G A Jamieson
Journal:  Blood       Date:  1992-09-01       Impact factor: 22.113

2.  Presence of the entire coding region of GP IV mRNA in Nak(a)-negative platelets.

Authors:  H Kashiwagi; S Honda; H Take; H Mizutani; Y Imai; T Furubayashi; Y Tomiyama; Y Kurata; T Yonezawa
Journal:  Int J Hematol       Date:  1993-04       Impact factor: 2.490

3.  Expression of GPIV and N(aka) antigen on monocytes in N(aka)-negative subjects whose platelets lack GPIV.

Authors:  H Take; H Kashiwagi; Y Tomiyama; S Honda; Y Honda; H Mizutani; T Furubayashi; T Karasuno; T Nishiura; Y Kanayama
Journal:  Br J Haematol       Date:  1993-07       Impact factor: 6.998

4.  Characterization of two alternatively spliced 5'-untranslated exons of the human CD36 gene in different cell types.

Authors:  K T Taylor; Y Tang; D A Sobieski; R H Lipsky
Journal:  Gene       Date:  1993-11-15       Impact factor: 3.688

5.  CD36 is a receptor for oxidized low density lipoprotein.

Authors:  G Endemann; L W Stanton; K S Madden; C M Bryant; R T White; A A Protter
Journal:  J Biol Chem       Date:  1993-06-05       Impact factor: 5.157

6.  Identification, primary structure, and distribution of CLA-1, a novel member of the CD36/LIMPII gene family.

Authors:  D Calvo; M A Vega
Journal:  J Biol Chem       Date:  1993-09-05       Impact factor: 5.157

7.  A novel polymorphism in glycoprotein IV (replacement of proline-90 by serine) predominates in subjects with platelet GPIV deficiency.

Authors:  H Kashiwagi; S Honda; Y Tomiyama; H Mizutani; H Take; Y Honda; S Kosugi; Y Kanayama; Y Kurata; Y Matsuzawa
Journal:  Thromb Haemost       Date:  1993-05-03       Impact factor: 5.249

8.  Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36.

Authors:  N A Abumrad; M R el-Maghrabi; E Z Amri; E Lopez; P A Grimaldi
Journal:  J Biol Chem       Date:  1993-08-25       Impact factor: 5.157

9.  c-kit Gene was not transcribed in cultured mast cells of mast cell-deficient Wsh/Wsh mice that have a normal number of erythrocytes and a normal c-kit coding region.

Authors:  T Tono; T Tsujimura; U Koshimizu; T Kasugai; S Adachi; K Isozaki; S Nishikawa; M Morimoto; Y Nishimune; S Nomura
Journal:  Blood       Date:  1992-09-15       Impact factor: 22.113

10.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.

Authors:  T Furitsu; T Tsujimura; T Tono; H Ikeda; H Kitayama; U Koshimizu; H Sugahara; J H Butterfield; L K Ashman; Y Kanayama
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

View more
  14 in total

1.  Molecular basis of human CD36 gene mutations.

Authors:  Monika Ewa Rać; Krzysztof Safranow; Wojciech Poncyljusz
Journal:  Mol Med       Date:  2007 May-Jun       Impact factor: 6.354

2.  Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects.

Authors:  S Nozaki; H Kashiwagi; S Yamashita; T Nakagawa; B Kostner; Y Tomiyama; A Nakata; M Ishigami; J Miyagawa; K Kameda-Takemura
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

3.  CD36 antisense expression in 3T3-F442A preadipocytes.

Authors:  Z Sfeir; A Ibrahimi; E Amri; P Grimaldi; N Abumrad
Journal:  Mol Cell Biochem       Date:  1999-02       Impact factor: 3.396

4.  CD36 mediates long-chain fatty acid transport in human myocardium: complete myocardial accumulation defect of radiolabeled long-chain fatty acid analog in subjects with CD36 deficiency.

Authors:  S Nozaki; T Tanaka; S Yamashita; K Sohmiya; T Yoshizumi; F Okamoto; Y Kitaura; C Kotake; H Nishida; A Nakata; T Nakagawa; K Matsumoto; K Kameda-Takemura; S Tadokoro; Y Kurata; Y Tomiyama; K Kawamura; Y Matsuzawa
Journal:  Mol Cell Biochem       Date:  1999-02       Impact factor: 3.396

5.  A two-amino acid insertion in the Cys146- Cys167 loop of the alphaIIb subunit is associated with a variant of Glanzmann thrombasthenia. Critical role of Asp163 in ligand binding.

Authors:  S Honda; Y Tomiyama; M Shiraga; S Tadokoro; J Takamatsu; H Saito; Y Kurata; Y Matsuzawa
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

6.  CD36 binds oxidized low density lipoprotein (LDL) in a mechanism dependent upon fatty acid binding.

Authors:  Anthony G Jay; Alexander N Chen; Miguel A Paz; Justin P Hung; James A Hamilton
Journal:  J Biol Chem       Date:  2015-01-01       Impact factor: 5.157

Review 7.  The role and regulation of CD36 for fatty acid imaging of the heart: implications in diabetes mellitus and chronic kidney disease.

Authors:  Omer Aras; Vasken Dilsizian
Journal:  J Nucl Cardiol       Date:  2007 May-Jun       Impact factor: 3.872

8.  Preliminary studies on CD36 gene in type 2 diabetic patients from north India.

Authors:  Sunaina Gautam; C G Agrawal; Hemant Kumar Bid; Monisha Banerjee
Journal:  Indian J Med Res       Date:  2011-07       Impact factor: 2.375

9.  Positive selection of a CD36 nonsense variant in sub-Saharan Africa, but no association with severe malaria phenotypes.

Authors:  Andrew E Fry; Anita Ghansa; Kerrin S Small; Alejandro Palma; Sarah Auburn; Mahamadou Diakite; Angela Green; Susana Campino; Yik Y Teo; Taane G Clark; Anna E Jeffreys; Jonathan Wilson; Muminatou Jallow; Fatou Sisay-Joof; Margaret Pinder; Michael J Griffiths; Norbert Peshu; Thomas N Williams; Charles R Newton; Kevin Marsh; Malcolm E Molyneux; Terrie E Taylor; Kwadwo A Koram; Abraham R Oduro; William O Rogers; Kirk A Rockett; Pardis C Sabeti; Dominic P Kwiatkowski
Journal:  Hum Mol Genet       Date:  2009-04-29       Impact factor: 6.150

10.  Comparative Studies of Vertebrate Platelet Glycoprotein 4 (CD36).

Authors:  Roger S Holmes
Journal:  Biomolecules       Date:  2012-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.